[{"orgOrder":0,"company":"GL Pharm Tech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"GL Pharm Tech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GL Pharm Tech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GL Pharm Tech \/ Undisclosed"},{"orgOrder":0,"company":"Kuopio University Hospital","sponsor":"Admescope","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FINLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Kuopio University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Prolonged Release","sponsorNew":"Kuopio University Hospital \/ Admescope","highestDevelopmentStatusID":"11","companyTruncated":"Kuopio University Hospital \/ Admescope"},{"orgOrder":0,"company":"Kuopio University Hospital","sponsor":"Admescope","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FINLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Kuopio University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kuopio University Hospital \/ Admescope","highestDevelopmentStatusID":"11","companyTruncated":"Kuopio University Hospital \/ Admescope"},{"orgOrder":0,"company":"Kuopio University Hospital","sponsor":"Admescope","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"FINLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Kuopio University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kuopio University Hospital \/ Admescope","highestDevelopmentStatusID":"11","companyTruncated":"Kuopio University Hospital \/ Admescope"},{"orgOrder":0,"company":"Maastricht University Medical Center","sponsor":"ZonMw | Envida, Maastricht, The Netherlands","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Maastricht University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Maastricht University Medical Center \/ ZonMw | Envida, Maastricht, The Netherlands","highestDevelopmentStatusID":"11","companyTruncated":"Maastricht University Medical Center \/ ZonMw | Envida, Maastricht, The Netherlands"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Oncology","graph2":"Phase IV","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Oncology","graph2":"Phase IV","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Oncology","graph2":"Phase IV","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Oncology","graph2":"Phase IV","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Oncology","graph2":"Phase IV","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Oncology","graph2":"Phase IV","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"IRELAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Prolonged Release","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Prolonged Release","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Prolonged Release","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Prolonged Release","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Urology","graph2":"Phase II","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Grunenthal","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Grunenthal","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grunenthal \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Grunenthal \/ Undisclosed"},{"orgOrder":0,"company":"Stanford University","sponsor":"Mayo Clinic | Vanderbilt University Medical Center | Albert Einstein College of Medicine | University of British Columbia | Endeavor Health","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase IV","graph3":"Stanford University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Stanford University \/ Mayo Clinic | Vanderbilt University Medical Center | Albert Einstein College of Medicine | University of British Columbia | Endeavor Health","highestDevelopmentStatusID":"11","companyTruncated":"Stanford University \/ Mayo Clinic | Vanderbilt University Medical Center | Albert Einstein College of Medicine | University of British Columbia | Endeavor Health"},{"orgOrder":0,"company":"Lotus Clinical Research","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Lotus Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lotus Clinical Research \/ Mallinckrodt Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Lotus Clinical Research \/ Mallinckrodt Pharmaceuticals"},{"orgOrder":0,"company":"VistaPharm, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"VistaPharm, Inc.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VistaPharm, Inc. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"VistaPharm, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"University of British Columbia","sponsor":"Purdue Pharma | International Collaboration on Repair Discoveries | Vancouver Coastal Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"University of British Columbia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of British Columbia \/ Purdue Pharma | International Collaboration on Repair Discoveries | Vancouver Coastal Health","highestDevelopmentStatusID":"11","companyTruncated":"University of British Columbia \/ Purdue Pharma | International Collaboration on Repair Discoveries | Vancouver Coastal Health"},{"orgOrder":0,"company":"SWOG Cancer Research Network","sponsor":"Proteus","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"SWOG Cancer Research Network","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Patch","sponsorNew":"SWOG Cancer Research Network \/ Proteus","highestDevelopmentStatusID":"1","companyTruncated":"SWOG Cancer Research Network \/ Proteus"},{"orgOrder":0,"company":"Assertio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Assertio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Assertio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Assertio Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Assertio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Assertio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Assertio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Assertio Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pain Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Pain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pain Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pain Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pain Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Pain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pain Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pain Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pain Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pain Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pain Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pain Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pain Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pain Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pain Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pain Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pain Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pain Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pain Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pain Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pain Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pain Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pain Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pain Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pain Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pain Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Elite Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Elite Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Elite Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Elite Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Purdue Pharmaceuticals L.P","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Purdue Pharmaceuticals L.P","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Purdue Pharmaceuticals L.P \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Purdue Pharmaceuticals L.P \/ Undisclosed"},{"orgOrder":0,"company":"Purdue Pharmaceuticals L.P","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Purdue Pharmaceuticals L.P","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Purdue Pharmaceuticals L.P \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Purdue Pharmaceuticals L.P \/ Undisclosed"},{"orgOrder":0,"company":"Purdue Pharmaceuticals L.P","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Purdue Pharmaceuticals L.P","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Purdue Pharmaceuticals L.P \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Purdue Pharmaceuticals L.P \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Collegium Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Collegium Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Collegium Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Collegium Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Elite Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Elite Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elite Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Elite Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Lifetree Clinical Research Center, Salt Lake City, Utah","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Lifetree Clinical Research Center, Salt Lake City, Utah","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Lifetree Clinical Research Center, Salt Lake City, Utah"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Ambit Biosciences | Kern Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ Ambit Biosciences | Kern Medical Center","highestDevelopmentStatusID":"6","companyTruncated":"Mayo Clinic \/ Ambit Biosciences | Kern Medical Center"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BRAZIL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eurofarma Laboratorios S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Undisclosed"},{"orgOrder":0,"company":"International Clinical Research Institute","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"International Clinical Research Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"International Clinical Research Institute \/ Mallinckrodt Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"International Clinical Research Institute \/ Mallinckrodt Pharmaceuticals"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Centre for Addiction and Mental Health","sponsor":"University of Toronto","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Centre for Addiction and Mental Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Controlled Release","sponsorNew":"Centre for Addiction and Mental Health \/ University of Toronto","highestDevelopmentStatusID":"11","companyTruncated":"Centre for Addiction and Mental Health \/ University of Toronto"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Purdue Pharmaceuticals L.P","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Purdue Pharmaceuticals L.P","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Purdue Pharmaceuticals L.P \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Purdue Pharmaceuticals L.P \/ Undisclosed"},{"orgOrder":0,"company":"Purdue Pharmaceuticals L.P","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Purdue Pharmaceuticals L.P","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Purdue Pharmaceuticals L.P \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Purdue Pharmaceuticals L.P \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Purdue Pharmaceuticals L.P","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Purdue Pharmaceuticals L.P","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Purdue Pharmaceuticals L.P \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Purdue Pharmaceuticals L.P \/ Undisclosed"},{"orgOrder":0,"company":"Purdue Pharmaceuticals L.P","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Purdue Pharmaceuticals L.P","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Purdue Pharmaceuticals L.P \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Purdue Pharmaceuticals L.P \/ Undisclosed"},{"orgOrder":0,"company":"Purdue Pharmaceuticals L.P","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Purdue Pharmaceuticals L.P","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Purdue Pharmaceuticals L.P \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Purdue Pharmaceuticals L.P \/ Undisclosed"},{"orgOrder":0,"company":"Purdue Pharmaceuticals L.P","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Purdue Pharmaceuticals L.P","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Purdue Pharmaceuticals L.P \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Purdue Pharmaceuticals L.P \/ Undisclosed"},{"orgOrder":0,"company":"Purdue Pharmaceuticals L.P","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Purdue Pharmaceuticals L.P","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Purdue Pharmaceuticals L.P \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Purdue Pharmaceuticals L.P \/ Undisclosed"},{"orgOrder":0,"company":"Purdue Pharmaceuticals L.P","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Purdue Pharmaceuticals L.P","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Purdue Pharmaceuticals L.P \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Purdue Pharmaceuticals L.P \/ Undisclosed"},{"orgOrder":0,"company":"Purdue Pharmaceuticals L.P","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Purdue Pharmaceuticals L.P","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Purdue Pharmaceuticals L.P \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Purdue Pharmaceuticals L.P \/ Undisclosed"},{"orgOrder":0,"company":"Purdue Pharmaceuticals L.P","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Purdue Pharmaceuticals L.P","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Purdue Pharmaceuticals L.P \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Purdue Pharmaceuticals L.P \/ Undisclosed"},{"orgOrder":0,"company":"Purdue Pharmaceuticals L.P","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Purdue Pharmaceuticals L.P","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Purdue Pharmaceuticals L.P \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Purdue Pharmaceuticals L.P \/ Undisclosed"},{"orgOrder":0,"company":"Protega Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Protega Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Protega Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Protega Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mayo Clinic \/ Undisclosed"},{"orgOrder":0,"company":"Collegium Pharmaceutical","sponsor":"Ajay Wasan","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Oxycodone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Collegium Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Collegium Pharmaceutical \/ Ajay Wasan","highestDevelopmentStatusID":"11","companyTruncated":"Collegium Pharmaceutical \/ Ajay Wasan"}]
Find Clinical Drug Pipeline Developments & Deals for Oxycontin
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
